Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.98MP/E –Yield –
Lyell Immunopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lyell Immunopharma's enterprise value was $190.37M on Nov 11, 2026, against $143.43M a year earlier. Over the last 5 years it ranged from -$289.10M to $1.24B, with a median of $54.20M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $190.37M | -30.6% |
| 2025 | Dec 31, 2025 | $274.24M | – |
| 2024 | Dec 31, 2024 | -$276.35M | – |
| 2023 | Dec 29, 2023 | -$86.81M | -140.1% |
| 2022 | Dec 30, 2022 | $216.73M | -82.5% |
| 2021 | Dec 31, 2021 | $1.24B | – |
See a number that looks wrong?